Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CAMP4 Therapeutics

CAMP4 Reports Third Quarter 2024 Financial Results
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Announces Pricing of Initial Public Offering
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
From CAMP4 Therapeutics
Via GlobeNewswire
Research from the Lab of CAMP4 Co-Founder Richard Young Shows That RNA Binding to Transcription Factors Fine-Tunes Gene Expression
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Therapeutics Appoints Veteran Drug Developer Ann Barbier, M.D., Ph.D. as Chief Medical Officer
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Presents First Preclinical Data Demonstrating the Therapeutic Potential of its RNA Actuating Platform at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Therapeutics Expands Leadership and Board of Directors
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes
From CAMP4 Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.